| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Niagen Bioscience, Inc. | Chief Financial Officer | Common Stock | 7.37K | $50.2K | $6.81 | Nov 14, 2025 | Direct |
| Niagen Bioscience, Inc. | Chief Financial Officer | Common Stock | 2.22K | $15.2K | $6.85 | Nov 14, 2025 | The reported securities are held by the reporting person's spouse. |
| 180 Life Sciences Corp. | CFO | Common Stock | 8.98K | $1.69K | $0.19 | Sep 4, 2023 | Direct |
| ChromaDex Corp. | Chief Financial Officer | Employee Stock Options (right to buy) | 17.2K | Feb 12, 2025 | Direct | ||
| 180 Life Sciences Corp. | CFO | Stock Option (Right to Buy) | 15K | Sep 4, 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| NAGE | Niagen Bioscience, Inc. | Nov 14, 2025 | 2 | $45.6K | 4 | Nov 17, 2025 | Chief Financial Officer |
| CDXC | ChromaDex Corp. | Feb 12, 2025 | 1 | $0 | 4 | Feb 14, 2025 | Chief Financial Officer |
| CDXC | ChromaDex Corp. | Nov 22, 2024 | 1 | $21.4K | 4 | Nov 25, 2024 | Chief Financial Officer |
| CDXC | ChromaDex Corp. | Oct 21, 2024 | 1 | $0 | 4 | Oct 23, 2024 | Chief Financial Officer |
| CDXC | ChromaDex Corp. | Oct 21, 2024 | 0 | $0 | 3 | Oct 23, 2024 | Chief Financial Officer |
| ATNF | 180 Life Sciences Corp. | Sep 4, 2023 | 1 | $0 | 4 | Sep 6, 2023 | CFO |
| ATNF | 180 Life Sciences Corp. | May 18, 2023 | 1 | $5.21K | 4 | May 19, 2023 | CFO |
| ATNF | 180 Life Sciences Corp. | Dec 10, 2021 | 1 | $14.7K | 4 | Dec 13, 2021 | Interim CFO |